Biography
Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and is an active member of the VA national Lung Cancer Working Group and Lung Cancer Precision Oncology Program. In 2023, she was elected President the Association of Northern California Oncologists (ANCO), where she displays her passion for patient advocacy and also for clinician education by helping to organize Bay Area focused continuing medical education programs. She is the VA site director for the Stanford fellowship program and leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.
View Full Biography
Professional Summary
Education & Certifications
- Fellowship, Stanford University Hematology and Oncology Fellowship, CA (2011)
- Board Certification: American Board of Internal Medicine, Medical Oncology (2011)
- Residency: Stanford University Hospital -Clinical Excellence Research Center (2007) CA
-
- Internship: Stanford University Hospital -Clinical Excellence Research Center (2005) CA
- Medical Education: University of Massachusetts Medical Center (2004) MA
Memberships
- Member, International Association for the Study of Lung Cancer (IASLC) (2009 - Present)
- Member, American Society of Clinical Oncology (ASCO) (2008 - Present)
-
Administrative Appointments
- Associate Program Director, Oncology Fellowship, Stanford University (2015 - Present)
- Chief, Oncology, VA Palo Alto Health Care System (2015 - Present)
-
Publications
-
Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?
Das, M., Abdelmaksoud, M. H. K., Loo, B. W., & Kothary, N. (2010). Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time? CURRENT TREATMENT OPTIONS IN ONCOLOGY, 11(1-2), 24–35. -
Vascular Disrupting Agents
Das, M., & Wakelee, H. (2010). Vascular Disrupting Agents. JOURNAL OF THORACIC ONCOLOGY, 5(12), S482–S483. -
Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer
Das, M., Donington, J. S., Murphy, J., Kozak, M., Eclov, N., Whyte, R. I., … Wakelee, H. (2011). Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 12(5), 280–85. -
-
Angiogenesis Inhibitors
Das, M., & Wakelee, H. (2011). Angiogenesis Inhibitors. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1801–S1802. -
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., Hsieh, H. B., … Bruce, R. H. (2012). ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer , 77(2), 421–26. -
Angiogenesis inhibitors.
Das, M., & Wakelee, H. (2012). Angiogenesis inhibitors. Journal of Thoracic Oncology , 7(16), S397–8. -
Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study
Das, M., & Wakelee, H. (2012). Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study. JOURNAL OF THORACIC DISEASE, 4(6), 558–61. -
A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements.
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., … Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. Clinical Lung Cancer, 14(5), 592–95. -
A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17–E18. -
Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.
Das, M., & Wakelee, H. (2014). Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC. Translational Lung Cancer Research, 3(6), 397–99. -
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. LUNG CANCER, 89(3), 280–86. -
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., … Neal, J. W. (2017). ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology . -
Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., … Diehn, M. (2017). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., & Wakelee, H. A. (2013). ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)
Neal, J. W., Wakelee, H. A., Feliciano, J. L., Goldberg, S. B., Morgensztern, D., Das, M. S., … Sequist, L. V. (2014). A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS
Nguyen, K.-S. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., … Neal, J. W. (2013). VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., … Blayney, D. (2013). PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER. JOURNAL OF THORACIC ONCOLOGY, 8, S1324. -
Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., … Diehn, M. (2018). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Anti-angiogenic Agents in Metastatic NSCLC
Das, M., & Wakelee, H. (2014). Anti-angiogenic Agents in Metastatic NSCLC. LUNG CANCER,4TH EDITION, 527–40. -
Stage IIIB and IV NSCLC: Primary Therapy
Das, M., & Wakelee, H. (2011). Stage IIIB and IV NSCLC: Primary Therapy. LUNG CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT, 183–95. -
BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY
Das, M., & Wakelee, H. (2012). BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY. JOURNAL OF THORACIC ONCOLOGY, 7(11), S442–S443. -
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., … Wakelee, H. A. (2018). A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. -
Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung.
Das, M., & Tisch, A. H. (2017). Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung. Journal of the Advanced Practitioner in Oncology, 8(3), 267–72. -
Patterns of Care and Health Disparities for Patients With Stage I Non-small Cell Lung Cancer in the US
Harris, J. P., Nwachukwu, C. R., Loo, B. W., Das, M., & Diehn, M. (2017). Patterns of Care and Health Disparities for Patients With Stage I Non-small Cell Lung Cancer in the US. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E399. -
Assessment of patients' satisfaction of an innovative oncology telemedicine clinic.
Nguyen, K.-S. H., El-Masry, M., Tham, M., Howard, L., Ventura, R., Chwick, K., & Das, M. S. (2014). Assessment of patients' satisfaction of an innovative oncology telemedicine clinic. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
Harris, J. P., Nwachukwu, C., Qian, Y., Pollom, E., Loo, B. W., Das, M., & Diehn, M. (2018). Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 124, 76–85. -
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., … Wakelee, H. A. (2018). A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 82(3), 541–50. -
Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer
Harris, J. P., Nwachukwu, C., Qian, Y., Pollom, E., Loo, B. W., Das, M., & Diehn, M. (2018). Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. LUNG CANCER, 124, 76–85. -
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., … Wakelee, H. A. (2019). Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 134, 42–45. -
Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., … Diehn, M. (2019). Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes
Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2019). Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 105(1), S113. -
Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27). -
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. NATURE CANCER, 1. -
A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.
Riess, J. W., Jahchan, N. S., Das, M., Zach Koontz, M., Kunz, P. L., Wakelee, H. A., … Neal, J. W. (2020). A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment and Research Communications, 23, 100174. -
Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.
Myall, N. J., & Das, M. (2020). Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. Clinics in Chest Medicine, 41(2), 211–22. -
The Project Baseline Health Study: a step towards a broader mission to map human health
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., … Wong, C. A. (2020). The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ DIGITAL MEDICINE, 3(1), 84. -
Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan, M., & Das, M. (2020). Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Current Treatment Options in Oncology, 21(8), 64. -
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., … Diehn, M. (2020). Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. -
KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., … Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
Moding, E. J., Esfahani, M. S., Nabet, B., Liu, Y., Chabon, J. J., He, J., … Diehn, M. (2020). A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., … Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery. -
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W., … Wang, S. X. (2021). Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clinical Chemistry. -
Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.
Hellyer, J. A., Aredo, J. V., Das, M., Ramchandran, K., Padda, S. K., Neal, J. W., & Wakelee, H. A. (2021). Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
The Project Baseline Health Study: a step towards a broader mission to map human health.
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., … Wong, C. A. (2020). The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ Digital Medicine, 3(1), 84. -
A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., … Diehn, M. (2020). A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., … Wakelee, H. (2021). Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib. JOURNAL OF THORACIC ONCOLOGY, 16(4), S773–S774. -
Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers
Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., … Ramchandran, K. (2021). Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., … Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., … Diehn, M. (2021). Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Machine Learning Radiomics Model for Early Identification of Small-Cell Lung Cancer on Computed Tomography Scans.
Shah, R. P., Selby, H. M., Mukherjee, P., Verma, S., Xie, P., Xu, Q., … Napel, S. (2021). Machine Learning Radiomics Model for Early Identification of Small-Cell Lung Cancer on Computed Tomography Scans. JCO Clinical Cancer Informatics, 5, 746–757. -
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., & Neal, J. W. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer. -
Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., … Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature Cancer, 1(2), 176–183. -
Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management
Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., … Katsumoto, T. R. (2021). Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC. -
Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., … Raj, R. (2021). Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC. -
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das, M., Padda, S. K., Weiss, J., & Owonikoko, T. K. (2021). Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion. Advances in Therapy. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e435. -
A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). International Journal of Radiation Oncology, Biology, Physics, 111(3S), S89–S90. -
Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC).
Marar, M., Bryant, A. K., Nalawade, V., Das, M., Jr, B. W., Diehn, M., … Vitzthum, L. (2021). Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology, Biology, Physics, 111(3S), e447. -
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Marar, M., Bryant, A. K., Nalawade, V., Das, M., Loo, B. W., Diehn, M., … Vitzthum, L. (2021). Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., … Wakelee, H. A. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. -
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., … Wakelee, H. A. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. -
Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study.
Califf, R. M., Wong, C., Doraiswamy, P. M., Hong, D. S., Miller, D. P., & Mega, J. L. (2022). Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study. BMJ Open, 12(1), e054741. -
Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., … Vitzthum, L. K. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics. -
Improving supportive care for patients with Thoracic Malignancies - A randomized controlled trial.
Patel, M. I., Banks, L., & Das, M. (2022). Improving supportive care for patients with Thoracic Malignancies - A randomized controlled trial. Contemporary Clinical Trials Communications, 28, 100929. -
Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., … Neal, J. W. (2022). Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer. -
Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., … Vitzthum, L. K. (2022). Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology. -
Early Outcomes and Toxicity with Concurrent Chemotherapy and Hypofractionated Radiation Therapy in Patients with Non-Small Cell Lung Cancer
Hui, C., Marquez, C., Lau, B., Von Eyben, R., Das, M., Myall, N., … Vitzthum, L. (2022). Early Outcomes and Toxicity with Concurrent Chemotherapy and Hypofractionated Radiation Therapy in Patients with Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS. -
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
Hui, C., Qu, V., Wang, J.-Y. Y., von Eyben, R., Chang, Y.-C. C., Chiang, P.-L. L., … Pollom, E. (2022). Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Journal of Neuro-Oncology. -
Improving supportive care for patients with thoracic cancer.
Banks, L. C., Kapphahn, K., Das, M., Wujcik, D., Stricker, C. T., Shanbhag, L., … Patel, M. I. (2022). Improving supportive care for patients with thoracic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Improving Supportive Care for Patients with Thoracic Cancer
Banks, L. C., Wujcik, D., Stricker, C., Das, M., Shanbhag, L., Lin, S., & Patel, M. (2022). Improving Supportive Care for Patients with Thoracic Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+Non-small Cell Lung Cancer
Das, M., Ogale, S., Johnson, A., Nguyen, C., Bhagwakar, J., & Jovanoski, N. (2022). Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival
Wu, J. T., La, J., Han, S., Das, M., Glover, M., Scobie, M., … Kelley, M. (2022). The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series.
Nief, C. A., No, H. J., Louie, C. Y., Vitzthum, L., & Das, M. (2022). Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series. Clinical Lung Cancer. -
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128. -
Understanding the barriers and experiences of veterans with lung cancer
Lopez, C., Murillo, A., Das, M., & Patel, M. I. (2022). Understanding the barriers and experiences of veterans with lung cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Characterizing Metastatic Non-Small Cell Lung Cancer Presenting to an Academic Medical Center in an Era of Changing Treatment Paradigms
Raja, N., No, H. J., Von Eyben, R., Das, M., Roy, M., Myall, N., … Vitzthum, L. (2022). Characterizing Metastatic Non-Small Cell Lung Cancer Presenting to an Academic Medical Center in an Era of Changing Treatment Paradigms. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., … Pollom, E. (2022). Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
Das, M., Ogale, S., Jovanoski, N., Johnson, A., Nguyen, C., Bhagwakar, J., & Lee, J. S. (2023). Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer. Immunotherapy. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., … Vitzthum, L. K. (2023). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Are We Getting Closer to the Promise of Cure? New Progress and Future Directions in the Treatment of Early-Stage Non-Small-Cell Lung Cancer.
Das, M. (2023). Are We Getting Closer to the Promise of Cure? New Progress and Future Directions in the Treatment of Early-Stage Non-Small-Cell Lung Cancer. JCO Oncology Practice, OP2300170. -
Impact of PD-L1 Status on Survival on Immunotherapy Monotherapy in Real-World Patients with Poor Performance Status: A US Nationwide Veterans Affairs Study
Wu, J., Su, C., La, J., Corrigan, J., Das, M., Do, N., … Kelley, M. (2023). Impact of PD-L1 Status on Survival on Immunotherapy Monotherapy in Real-World Patients with Poor Performance Status: A US Nationwide Veterans Affairs Study. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy.
Patel, S. R., & Das, M. (2023). Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. Cancers, 15(16). -
Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., … Diehn, M. (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology. -
Understanding Barriers and Facilitators to High-Quality Cancer Care Among Veterans With Lung Cancer: A Qualitative Study.
Lopez, C., Murillo, A., Das, M., & Patel, M. I. (2023). Understanding Barriers and Facilitators to High-Quality Cancer Care Among Veterans With Lung Cancer: A Qualitative Study. JCO Oncology Practice, OP2300228. -
CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC.
Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., … Myall, N. (2023). CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC. International Journal of Radiation Oncology, Biology, Physics, 117(2S), e110. -
Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis.
Qu, F., Brough, S. C., Michno, W., Madubata, C. J., Hartmann, G. G., Puno, A., … Sage, J. (2023). Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis. Nature Cell Biology. -
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
Khurshid, H., Ismaila, N., Bian, J., Dabney, R., Das, M., Ellis, P., … Kalemkerian, G. P. (2023). Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2301435. -
Amivantamab vs Mobocertinib in Exon 20 NSCLC
Spira, A. I., Bestvina, C., Sabari, J. K., Das, M., & Nagasaka, M. (2023). Amivantamab vs Mobocertinib in Exon 20 NSCLC. ONCOLOGY-NEW YORK, 37(8), 340–342. -
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., … Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. -
Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., … Vitzthum, L. K. (2023). Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer. Clinical Lung Cancer. -
Randomized Trial of a Volunteer-Led Symptom Assessment Intervention on Documentation, Patient-Reported Outcomes, and Health Care Use Among Veterans With Lung Cancer.
Banks, L. K. C., Kapphahn, K., Das, M., & Patel, M. I. (2024). Randomized Trial of a Volunteer-Led Symptom Assessment Intervention on Documentation, Patient-Reported Outcomes, and Health Care Use Among Veterans With Lung Cancer. JCO Oncology Practice, OP2300557. -
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu, S., Chai, T., Garcia-Marques, F., Yin, Q., Hsu, E.-C. C., Shen, M., … Stoyanova, T. (2024). UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Reports. Medicine, 101381. -
Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Das, M. S., Myall, N. J., … Wakelee, H. A. (2023). Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure?
Salter, A. I., & Das, M. (2024). Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure? Translational Lung Cancer Research, 13(3), 673–677. -
Teleoncology in the Veterans Health Administration: Models of Care and the Veteran Experience.
Parikh, D. A., Rodgers, T. D., Passero, V. A., Chang, J. C., Tisdale, R., Kelley, M. J., & Das, M. (2024). Teleoncology in the Veterans Health Administration: Models of Care and the Veteran Experience. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 44(3), e100042. -
The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.
Wu, J. T.-Y., Corrigan, J., Su, C., Dumontier, C., La, J., Khan, A., … Fillmore, N. R. (2024). The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer. Cancer Immunology, Immunotherapy : CII, 73(9), 172. -
Ensuring precision medicine for veterans with lung cancer: A randomized clinical trial
Thomas, M., Gonzalez, H., Agrawal, M., Das, M., & Patel, M. I. (2024). Ensuring precision medicine for veterans with lung cancer: A randomized clinical trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals.
Myall, N. J., & Das, M. (2024). ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals. Current Problems in Cancer, 53, 101133. -
A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., 't Erve, I. van, … Neal, J. W. (2024). A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. -
[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
Levi, J., Das, M., Vasanawala, M. S., Behl, D., Pomper, M., Forde, P. M., … Chae, H.-D. D. (2024). [18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights.
Khurshid, H., Ismaila, N., Das, M., Kulkarni, S., Manochakian, R., Weinberg, F., & Kalemkerian, G. P. (2024). Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. JCO Oncology Practice, OP2400840.
-
Angiogenesis Inhibitors
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
- Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
- A Phase 1/2 Study to Evaluate MEDI4736
Practice Locations
Thoracic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Thoracic Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(58 reviews)
Excellent physician
She is such a caring and awesome doctor always makes me feel like I'm number 1
I enjoyed her demeanor and thoroughness. She explained things carefully in a manner that I understood.
Wonderful person, MD and specialist.
I'm very appreciative of Dr. Das.
Provides not just care but compassion.
I've been blessed to have Dr. Das as my doctor. She and her team have taken care of me extremely well.
I would be lost without Dr. Das. She is patient in explaining all results and has been with me every step of this journey. I can’t say enough about her. The entire thoracic oncology team has been top notch since day one.
Excellet, caring, comprehensive.
Dr Das is a very caring professional doctor
Seen previous comment. I'm grateful.
Millie Das had reviewed my information, responded to all my questions, informed me of a treatment plan.
I am very appreciative of having a choice for being seen by an oncologist and their team for the rest of my life as well as being able to self refer and have an appointment so quickly.
Millie Das is also an excellent communicator.
I have confidence entrusting my ongoing care to her.
Dr. Das is the best
helpful and caring provider.
She was nice.
Absolutely one of the best doctors I've ever had. Dr. Das is kind, friendly, compassionate, knowledgeable, and takes the time to answer all of my questions without making me feel rushed. I really wish she were my General Practitioner, but I suppose I'll have to settle for having the World's Greatest Oncologist instead!
Millie is a great doctor. She never rushes and knows every detail about my treatment, current condition... I can't say enough good about Dr Das,
Very friendly and helpful.
thanks for being so awesome
My doctor is the best
I adore Dr Das she is like my family and she has been an amazing doctor.
We felt that Dr. Das was very clear and forthcoming with all the information. The PA Jay was, as well. Very helpful.
Dr Das is a very empathetic and understanding person.
Very vare and helpful doctor. Listen to my questions and answered.
Dr Das took the time to explain the process to me
Great doctors. Fell very comfortable
Very excellent service
Always treats me very well, and provides great advice.
Feel better just having a doctor as skilled and knowledgable as she is.
Moves you through the process without delay. Very impressed with the swiftness in which i was treated with great success.
I think doctor is wonderful she is thorough and she explains things so I can understand
Dr Das is brilliant, empathic and thorough. She works hard for her patients.
Very patient and care to patients. and Answered all questions.
Very professional
Very interested in what I had to say
She is the best,
I feel very lucky to have such a caring and knowledgeable provider. I have the utmost confidence in her decisions and recommendations.
Dr Das was very kind and caring. We had alot of questions and she answered them with confidence and patience. I found that she explained things very well. We have alot of trust in her. She took my case to tumor board that day and called back with the results at the time she said she would. I am very greatful she is my oncologist.
At this point in my cancer care Dr. Das is doing what she needs to do. I am satisfied.
This team was awesome! Dr.Das kept me very informed and still is on top of it to ensure I receive the best treatment for my case.
very patient and help to my questions.
Everything went smoothly and my doctor was very good. She told me Everything i need to do.. She was very professional.
Very professional
,, , Dr. Das is a excellent doctor. She works well with team.
Excelkent b.
I am very pleased to have Dr Das as my oncologist. I feel like
I am finally going in the right direction for my disease.
Dr. Das is the greatest doctor I have ever t met. I completely trust her and believe she is giving me the best treatment for me.
Dr. Das' empathy & warmth exceeds my expectations.
Dr. Das is awesome.
It's a very good experience for me.
Dr. Das is exceptional. If my blood work has not come in she calls me later in the day she makes me feel special.
This was second opinion dr. follow up was excellent, appointment was informative.
Dr. Das is the best! I'm so thankful she's part of my life!
Our family are always appreciated the high devotion to duty of Doctor Das, Millie Snigdha.
So kind, smart and caring.
Excellent! Thanks Dr. Das and all the medical teams!
Dr. Das was the best.
The staff showed me respect. Efforts AND whatever I had concern about my health.
My doctor was treated as a member in a family.
Very satisfied about the direction to duty of the provider.
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records